Hypoxemia (Low Blood Oxygen): Causes, Symptoms And Treatment
Fibrosis And Carcinoid Syndrome: From Causation To Future Therapy
Modlin, I. M., Shapiro, M. D. & Kidd, M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum. Pathol. 35, 1440–1451 (2004).
Kloppel, G., Perren, A. & Heitz, P. U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann. NY Acad. Sci. 1014, 13–27 (2004).
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N. & Shapiro, M. D. Current status of gastrointestinal carcinoids. Gastroenterology 128, 1717–1751 (2005).
Eriksson, B. Et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors—well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87, 8–19 (2008).
Modlin, I. M., Shapiro, M. D. & Kidd, M. Carcinoid tumors and fibrosis: an association with no explanation. Am. J. Gastroenterol. 99, 2466–2478 (2004).
Morgan, J. G., Marks, C. & Hearn, D. Carcinoid tumors of the gastrointestinal tract. Ann. Surg. 180, 720–727 (1974).
Kidd, M., Shapiro, M. D. & Lye, K. D. Connective tissue growth factor (CTGF) is overexpressed in ileal carcinoids. Presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, January 22–24, San Francisco, California, USA (2004).
Hellman, P. Et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J. Surg. 26, 991–997 (2002).
Cai, Y. C. Et al. Florid angiogenesis in mucosa surrounding an ileal carcinoid tumor expressing transforming growth factor-α. Am. J. Surg. Pathol. 21, 1373–1377 (1997).
Kottra, J. J. & Dunnick, N. R. Retroperitoneal fibrosis. Radiol. Clin. North Am. 34, 1259–1275 (1996).
Dev., S., al Dujaily, S. & Subbuswamy, S. G. A case of ureteric obstruction, retroperitoneal fibrosis, and carcinoid tumour. Postgrad. Med. J. 75, 38–40 (1999).
Morand, J. J. Et al. Edema caused by retroperitoneal and tricuspid fibrosis with sclerodermatous cutaneous involvement disclosing carcinoid tumor. Apropos of a case and review of the literature [French]. Rev. Med. Interne. 18, 388–395 (1997).
Nelson, D. R., Stachura, M. E. & Dunlap, D. B. Ileal carcinoid tumor complicated by retroperitoneal fibrosis and a prolactinoma. Am. J. Med. Sci. 296, 129–133 (1988).
Scott, J., Foster, R. & Moore, A. Retroperitoneal fibrosis and nonmalignant ileal carcinoid. J. Urol. 138, 1435 (1987).
Gupta, A., Saibil, F., Kassim, O. & McKee, J. Retroperitoneal fibrosis caused by carcinoid tumour. Q. J. Med. 56, 367–375 (1985).
Moss, S. F. Et al. Pleural involvement in the carcinoid syndrome. Q. J. Med. 86, 49–53 (1993).
Tamagno, G., Goglia, U., Villa, G. & Murialdo, G. Lung fibrosis in carcinoid syndrome. Intern. Med. 46, 425–426 (2007).
Seo, J. W., Im, J. G., Kim, Y. W., Kim, J. H. & Sheppard, M. N. Synchronous double primary lung cancers of squamous and neuroendocrine type associated with cryptogenic fibrosing alveolitis. Thorax 46, 857–858 (1991).
Miller, R. R. & Muller, N. L. Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am. J. Surg. Pathol. 19, 653–658 (1995).
Kucuk, O. Et al. Lower extremity vasospasm associated with ischemic neuropathy, dermal fibrosis, and digital gangrene in a patient with carcinoid syndrome. Cancer 62, 1026–1029 (1988).
Bell, H. K., Poston, G. J., Vora, J. & Wilson, N. J. Cutaneous manifestations of the malignant carcinoid syndrome. Br. J. Dermatol. 152, 71–75 (2005).
Ratnavel, R. C., Burrows, N. P. & Pye, R. J. Scleroderma and the carcinoid syndrome. Clin. Exp. Dermatol. 19, 83–85 (1994).
Thorson, A., Biorck, G., Bjorkman, G. & Waldenstrom, J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am. Heart J. 47, 795–817 (1954).
Ferrans, V. J. & Roberts, W. C. The carcinoid endocardial plaque; an ultrastructural study. Hum. Pathol. 7, 387–409 (1976).
Norheim, I. Et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann. Surg. 206, 115–125 (1987).
Lundin, L., Norheim, I., Landelius, J., Oberg, K. & Theodorsson-Norheim, E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 77, 264–269 (1988).
Bhattacharyya, S., Toumpanakis, C., Caplin, M. E. & Davar, J. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am. J. Cardiol. 101, 378–381 (2008).
Bhattacharyya, S., Davar, J., Dreyfus, G. & Caplin, M. E. Carcinoid heart disease. Circulation 116, 2860–2865 (2007).
Howard, R. J. Et al. Carcinoid heart disease: diagnosis by two-dimensional echocardiography. Circulation 66, 1059–1065 (1982).
Zanettini, R. Et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39–46 (2007).
Bader, T. R., Semelka, R. C., Chiu, V. C., Armao, D. M. & Woosley, J. T. MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J. Magn. Reson. Imaging 14, 261–269 (2001).
Woodard, P. K., Feldman, J. M., Paine, S. S. & Baker, M. E. Midgut carcinoid tumors: CT findings and biochemical profiles. J. Comput. Assist. Tomogr. 19, 400–405 (1995).
Pantongrag-Brown, L., Buetow, P. C., Carr, N. J., Lichtenstein, J. E. & Buck, J. L. Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation. AJR Am. J. Roentgenol. 164, 387–391 (1995).
Horton, K. M., Lawler, L. P. & Fishman, E. K. CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics 23, 1561–1567 (2003).
Levy, A. D., Rimola, J., Mehrotra, A. K. & Sobin, L. H. From the archives of the AFIP: benign fibrous tumors and tumorlike lesions of the mesentery: radiologic–pathologic correlation. Radiographics 26, 245–264 (2006).
Coulier, B. Et al. Carcinoid tumor of the small intestine: MDCT findings with pathologic correlation. JBR-BTR 90, 507–515 (2007).
Lesurtel, M., Soll, C., Graf, R. & Clavien, P. A. Role of serotonin in the hepato-gastrointestinal tract: an old molecule for new perspectives. Cell. Mol. Life Sci. 65, 940–952 (2008).
Barnes, N. M. & Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083–1152 (1999).
Kim, D. Y. & Camilleri, M. Serotonin: a mediator of the brain–gut connection. Am. J. Gastroenterol. 95, 2698–2709 (2000).
Launay, J. M. Et al. Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J. Biol. Chem. 271, 3141–3147 (1996).
Nebigil, C. G., Launay, J. M., Hickel, P., Tournois, C. & Maroteaux, L. 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: crosstalk with tyrosine kinase pathways. Proc. Natl Acad. Sci. USA 97, 2591–2596 (2000).
Mason, J. W., Billingham, M. E. & Friedman, J. P. Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis. Circulation 56, 889–890 (1977).
Connolly, H. Et al. Valvular heart disease associated with fenfluramine–phentermine. N. Engl. J. Med. 337, 581–588 (1997).
Antonini, A. & Poewe, W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 6, 826–829 (2007).
Jagroop, I. A. & Mikhailidis, D. P. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 11, 161–165 (2000).
Gustafsson, B. I. Et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 111, 1517–1522 (2005).
Mekontso-Dessap, A. Et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113, 81–89 (2006).
Musunuru, S., Carpenter, J. E., Sippel, R. S., Kunnimalaiyaan, M. & Chen, H. A mouse model of carcinoid syndrome and heart disease. J. Surg. Res. 126, 102–105 (2005).
Wang, B. Et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am. J. Physiol. Heart Circ. Physiol. 293, H1282–H1290 (2007).
Ruddell, R. G. Et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am. J. Pathol. 169, 861–876 (2006).
Caplin, M. E. Et al. Carcinoid tumour. Lancet 352, 799–805 (1998).
Kulke, M. H. & Mayer, R. J. Carcinoid tumors. N. Engl. J. Med. 340, 858–868 (1999).
Jian, B. Et al. Serotonin mechanisms in heart valve disease I: serotonin-induced upregulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am. J. Pathol. 161, 2111–2121 (2002).
Moller, J. E. Et al. Factors associated with progression of carcinoid heart disease. N. Engl. J. Med. 348, 1005–1015 (2003).
Nilsson, C. L., Brodin, E. & Ekman, R. Substance P and related peptides in porcine cortex: whole tissue and nuclear localization. J. Chromatogr. A 800, 21–27 (1998).
Chaudhry, A., Funa, K. & Oberg, K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. 32, 107–114 (1993).
Waltenberger, J. Et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am. J. Pathol. 142, 71–78 (1993).
Kidd, M. Et al. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J. Gastroenterol. 13, 5208–5216 (2007).
Lal, A. & Chen, H. Treatment of advanced carcinoid tumors. Curr. Opin. Oncol. 18, 9–15 (2006).
Bhattacharyya, S., Toumpanakis, C., Caplin, M. E. & Davar, J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am. J. Cardiol. 102, 938–942 (2008).
Ohrvall, U. Et al. Method for dissection of mesenteric metastases in midgut carcinoid tumors. World J. Surg. 24, 1402–1408 (2000).
Howell, S. B. Et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97, 845–851 (1982).
Moertel, C. G., Kvols, L. K. & Rubin, J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 67, 33–36 (1991).
Robertson, J. I. Carcinoid syndrome and serotonin: therapeutic effects of ketanserin. Cardiovasc. Drugs Ther. 4 (Suppl. 1), S53–S58 (1990).
Noppen, M., Jacobs, A., Van Belle, S., Herregodts, P. & Somers, G. Inhibitory effects of ranitidine on flushing and serum serotonin concentrations in carcinoid syndrome. Br. Med. J. (Clin. Res. Ed.) 296, 682–683 (1988).
Wymenga, A. N., de Vries, E. G., Leijsma, M. K., Kema, I. P. & Kleibeuker, J. H. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur. J. Cancer 34, 1293–1294 (1998).
Jacobsen, M. B. Ondansetron in carcinoid syndrome. Lancet 340, 185 (1992).
Hauso, O. Et al. Long-term serotonin effects in the rat are prevented by terguride. Regul. Pept. 143, 39–46 (2007).
Ciccarelli, E., Touzel, R., Besser, M. & Grossman, A. Terguride—a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. Fertil. Steril. 49, 589–594 (1988).
Greenblatt, D. Y. Et al. Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 12, 942–951 (2007).
Kunnimalaiyaan, M. & Chen, H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 17, 139–142 (2006).
Brown, P., Pappas, C., Frazier, K., Turnage, A. & Liu, Q. LX1032: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome. [Abstract C16] Presented at the 6th Annual Conference of the European Neuroendocrine Tumor Society: 2009 March 5–7, Granada, Spain.
What To Know About Mucus In Cystic Fibrosis
Cystic fibrosis (CF) mucus can clog the lungs and digestive tract. Although there is no cure for CF, medications and therapies can help thin this mucus.
Cystic fibrosis (CF) affects approximately 35,000 people in the United States. It is a genetic disorder that can result in serious damage to your lungs and digestive tract. You may have a hard time breathing or absorbing nutrients if you have CF.
CF is a progressive condition where thickened mucus builds up inside the body, which can damage vital organs over time. While there is no cure, treatments focusing on thinning the mucus and improving airflow are extending the lives of people with CF.
Learn more about cystic fibrosis.
As a result of a genetic mutation to the cystic fibrosis transmembrane conductance regulator (CFTR) gene, mucus and other bodily fluids are thicker and stickier in people with CF.
This thickness occurs because the CFTR gene mutation affects the way salt and water move into and out of cells. Changes in the CFTR gene affect cells that produce sweat, mucus, and digestive enzymes.
CF mucus may clog the lungs, pancreas, liver, and intestines.
When CF mucus clogs the lungs, breathing problems and infections may become a concern.
Enzymes necessary for digestion may not reach the gut when the pancreas is affected by thick CF mucus. When the intestines are also affected by CF mucus, it can make it difficult to absorb enough nutrients.
Typically, when mucus covers the tiny hairlike structures called cilia in the lungs, it is swept up to the nose and mouth so it can exit the body. Thicker CF mucus sticks to the cilia, though. This interferes with the typical process and makes it more difficult to clear mucus out of the lungs.
Extra mucus in the lungs can lead to blockages, infections, and damage to structures inside and outside the lungs.
There is no cure for CF, but medicines and therapies can be useful in helping to thin the mucus and reduce related complications.
Some of the drugs that may reduce CF mucus and related symptoms include:
Surgical treatment options may include:
To help break up mucus in the chest and make it easier to cough up, you may have chest physical therapy several times a day with or without mechanical devices.
A doctor may also suggest oxygen therapy or ventilator support to help improve the amount of air in your body.
The predicted median survival age for a child born in the United States with CF was 48.4 years in 2019, and this number is expected to continue to climb.
The life expectancy for those with CF has grown in recent years thanks to the development of new drugs and therapy techniques. Additionally, newborn screening and prenatal testing have allowed for earlier interventions and family education.
What are the three major symptoms of cystic fibrosis?Individuals with CF may have salty skin. They can experience frequent lung infections and cough up mucus. They may also have greasy and foul-smelling stools.
What does cystic fibrosis stool look like?People with CF may experience constipation or have large, greasy stools. These stools can have a foul smell and may float because of the large amount of gas they contain.
When will you know if your baby has cystic fibrosis?All babies in the United States are tested for CF as part of their newborn screening. You can also test your developing baby for CF as early as 10 weeks into your pregnancy.
The thick, sticky mucus that builds up in the lungs and intestines of people with CF can make it hard to breathe and properly digest food. You may also experience frequent lung infections if you have CF.
Advances in medical treatments are increasing the life expectancy of people with CF. A combination of medications and therapies may be helpful in thinning out the mucus associated with CF so you can live a full, productive life. It's important to discuss your treatment plan with your doctor since every individual's needs are different.
Honeycomb Table
Your first 3D print probably seemed pretty amazing. But if you revisit it after a few years, you'll likely notice it wasn't nearly as good as you thought. We improve our printers and our processes and the new better results become normal. If you have a laser cutter, you may go through the same iteration. At first, you are happy just to get scorch marks on the workpiece. But when you move to cutting, you want cleaner cuts. You put tape over the work, add air assist, and invest in a honeycomb bed. Each step gets you better results, but you can always improve.
[The Louisiana Hobby Guy] (also known as [Rich]) knows a lot about the practical side of lasers. He suggests using standoff pins to not just secure the part to the honeycomb bed but lift it up a little, allowing air to flow under the part and lets the laser easily cut all the way through. You can see them in action in the video below.
This is a cheap upgrade to prevent flashback when cutting. [Rich] explains how to size them properly and even how to make your own if you don't want to buy them off the shelf. You can laser cut hold-down pins from plans [Rich] provides, although he prefers to 3D print them, and you can do that, too. Most beds look similar, but if yours is an oddball, you might have to modify them slightly. He has regular dog clamps and the antiflashback standoffs, so you can make some of each. You can also buy them online. Most do not have the antiflashback feature, but at least one vendor that [Rich] points out does have them
If you don't like the ones [Rich] shows, you can find 3D models for similar pins in the usual places. You can also design them yourself if you want them exactly how you want.
A good thing to add to your laser cutting workflow. [Rich's] channel is full of great stuff. If you want to know more about air assist, we've added it to our cutters. If you are serious about precision cuts, know your kerf, too.
Continue reading "Getting A Rise With Laser Cutting" →
Comments
Post a Comment